STAT+: With new diabetes drug data, Eli Lilly is taking aim at obesity

Eli Lilly released new data Thursday showing that an injectable diabetes drug it is developing, tirzepatide, can lead to substantial weight loss in people with obesity.

The Phase 3 study compared three doses of tirzepatide to placebo. According to a press release, patients on the 5-milligram dose lost 35 pounds, or 16% of their body weight; those receiving 10 milligrams lost 49 pounds, or 21.4%; and those who received the top 15-milligram dose lost 22.5%, or 52 pounds. In contrast, those on placebo lost 5 pounds, or 2.4% of their body weight.

Continue to STAT+ to read the full story…